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The different steps of a proteomics analysis workﬂow generate a plethora of features for each extracted
proteomic object (a protein spot in 2D gel electrophoresis (2-DE), or a peptide peak in liquid chromatog-
raphy–mass spectrometry (LC–MS) analysis). Yet, the joint visualization of multiple object features on 2D
gel-like maps is rather limited in currently available proteomics software packages. We introduce a new,
simple, and intuitive visualization method that utilizes spheres to represent proteomic objects on proteo-
mic feature maps, and exploits the spheres size and color to provide simultaneous visualization of user-
selected feature pairs. Our contribution, a uniﬁed and ﬂexible visualization mechanism that can be easily
applied at any stage of a 2-DE or a LC–MS based differential proteomics study, is demonstrated and dis-
cussed using ﬁve representative scenarios. The joint visualization of proteomic object features and their
spatial distribution is a powerful tool for inspecting and comparing the proteomics analysis results,
attracting the users attention to useful information, such as differential expression trends and patterns,
and even assisting in the evaluation and reﬁnement of a proteomics experiment.
 2009 Elsevier Inc. All rights reserved.1. Background
Proteomics is the ﬁeld concerned with the large-scale analysis
of complex protein mixtures, including protein identiﬁcation and
quantiﬁcation, as well as the determination of protein modiﬁca-
tions, interactions, activities and function [1–3]. Differential pro-
teomics, which focuses on the comparison of proteomes in
different biological states (e.g., normal vs. diseased cells, diseased
vs. treated cells), encompasses several gel and non-gel based ap-
proaches which aim at ﬁnding proteins that can mark reliably dif-
ferent physiopathological states [4]. A typical proteomic analysis
workﬂow includes the application of a separation method followed
by mass spectrometry (MS)-based identiﬁcation. The most com-
mon separation methods are 2D gel electrophoresis (2-DE) and
high performance Liquid Chromatography (LC), often used comple-
mentary to each other in a proteomic analysis study [5].
The main steps of a typical 2-DE-MS or LC–MS based differential
proteomics study are shown in Fig. 1. In the case of 2-DE, the gel
images are ﬁrst analyzed one by one (Fig. 1, panel 1 Image analysis
step) and subsequently, for each biological state of interest, a
matched set of images is constructed to facilitate the differentialll rights reserved.
ent of Informatics and Tele-
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.expression analysis based on statistical or quantitative methods
[4] (Fig. 1, panel 1 Differential analysis step). Finally, the differen-
tially expressed spots are selected for protein identiﬁcation, using
MS methods followed by database search (Fig. 1, panel 1 MS-based
Identiﬁcation step). In the case of a bottom-up LC–MS based exper-
iment (Fig. 1, panel 2), the workﬂow starts with the fractionation of
peptides generated by the tryptic digestion of protein extracts
using LC. The peptide fractions are then individually analyzed
using capillary chromatography hyphenated with nano-electro-
spray ionization (ESI) tandem mass spectrometry (MS/MS) [3]. In
order to impart a quantitative dimension and allow the simulta-
neous separation of different protein/peptide extracts from multi-
ple biological states and the MS/MS peptide quantiﬁcation, the
peptide extracts prior to the fractionation step are labeled with iso-
baric stable isotope reagents (e.g., iTRAQ [6]). The peptide MS/MS
spectra lead to the peptides relative quantiﬁcation and amino acid
sequencing, thus allowing the protein identiﬁcation using database
searching algorithms [7].
The proteomics analysis results and their associated metadata
often lead to interesting biological conclusions. However, their
interpretation tends to be laborious and time consuming for the
user, due to their heterogeneity (e.g., images, spreadsheets, and
database results), their distribution in multiple locations (e.g.,
workstations and software packages), and the limited visualization
methods for the proteomics data originating from different steps of
the analysis workﬂow.
Fig. 2. A proteomic object is associated with new features as it ‘‘passes” through the
different proteomics analysis steps. For example, a protein spot in a 2-DE
experiment gets its MW and pI values at the data generation step, a volume fold
factor and a statistical test p-value feature during the differential analysis step, the
score and coverage features at the protein identiﬁcation step, and so on.
Fig. 1. The main steps of a 2-DE based and a LC–MS based proteomics analysis
workﬂow. Proteomic Feature Maps have been created to summarize visually the
results obtained at the end of each analysis step.
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visually, in 2 or 3 dimensions, the large size data landscape pro-
duced by LC–MS experiments and therefore facilitate the tasks of
analysis and comparison. For example, MSight [8] and Pep3D [9–
11] present the LC–MS data as 2D gel-like images (retention time
(RT) vs. mass-to-charge ratio (m/z)) which help the user perform
differential proteome analysis, evaluate sample quality, identify
features of the separated peptides and so on. Moreover, a Pep3D
image can visualize two extra features, the precursor ions selected
for fragmentation and all peptides successfully identiﬁed by the
MS analysis, by adding colored boxes around the pixels which form
a peak. However, the visualization offered by MSight lacks in
encoding additional proteomic features, apart from the peaks
intensity that is shown using grayscale only, while Pep3D demands
additional effort to distinguish the color differences of the identiﬁ-
cation score due to the small-size boxes used. The work presented
by Linsen et al. in [12], displays LC–MS data in a 3D space and goes
a step beyond MSight and Pep3D by assigning color to the intensity
values of each peak, coloring peaks based on the condition under
which the maximum intensity has been observed and representing
the up and down regulation with red and green color, respectively.
A similar presentation was also used by Turner et al. in [13], where
in a 2D plot with circles representing peptides, color is used to dis-
play the ratio of expression levels of identical peptides in two dif-
ferent data sets. Yet, these efforts are limited on visualizing
features since they only exploit the color attribute.
Along the same lines, several software packages aim at integrat-
ing proteomics data collected during a 2-DE-MS proteomics work-
ﬂow (e.g., Bruker Proteinscape [14], GeneData Expressionist [15])
for enhancing the process of the results interpretation. However,
similar to the case of the LC–MS analysis, they do not offer the ﬂex-
ibility to combine any desired features extracted at different stages
of the proteomics analysis workﬂow and do not support their
simultaneous visualization. In addition, ‘‘bubble plots” have also
been introduced in proteomics in [16,17], where 2D gel spots
and Gas chromatography–mass spectrometry (GC–MS) peaks
respectively, are represented with circles or spheres. In this repre-
sentation though, only the ‘‘bubble” radius is exploited visually toindicate one speciﬁc feature (i.e., the spot abundance [16] and the
integrated peak area [17]]). The method we present here differs
from all the above approaches in that it offers not only the ﬂexibil-
ity of choosing any pair of features, but also the capability to visu-
alize them jointly on a gel-like map using spheres. This integrated
visualization approach provides a ﬂexible mechanism supporting
data interpretation, information extraction and validation of the
data analysis outcomes.
In this paper, we introduce a simple and intuitive, yet powerful
and uniﬁed, visualization approach, applicable to both 2-DE-MS
and LC–MS based proteomics analysis workﬂows. Speciﬁcally, we
demonstrate the use of spheres in representing features of proteo-
mic objects (i.e., protein gel spots or LC–MS peptide peaks) in syn-
thetic image maps. We show how to exploit the size and color
attributes of a sphere in order to visualize jointly and efﬁciently
(i.e., without involving a great deal of cognitive effort) two user-se-
lected features of proteomic objects resulting from an experiment.
By selecting different pairs of features, the user can easily create
maps which can:
 provide a better comprehension of the data set in its entirety,
 reveal differential expression trends of different biological
states, and
 assist the user to evaluate and possibly optimize the experimen-
tal conditions in order to obtain data of higher quality.
2. Results and discussion
A uniﬁed view of the 2-DE-MS and LC–MS approaches can be
established from a data processing and visualization perspective.
This is possible because both approaches basically generate proteo-
mic objects, (i.e., protein spots in 2-DE or peptide peaks in LC–MS
based experiments) and place them on a 2D map. A proteomic
object located at a (x, y) position on a map, corresponds to the
(isoelectric point (pI), molecular weight (MW)) spot, in the case of
a 2-DE gel, or to the (m/z, RT) peptide peak, in the case of a LC–MS
density plot. Therefore, step 1 in the two workﬂows shown in
Fig. 1, is the process which creates the proteomic objects and places
them at speciﬁc map locations. Every subsequent workﬂow step is
a process which adds new features to already created objects, as
shown in Fig. 2. For example, features such as the fold factor or
the p-value of a t-test are added to a spot object by the differential
analysis process; score and coverage are added by the MS-based
identiﬁcation analysis process that follows, and the feature of
molecular function, from the metadata analysis step based on the
Gene Ontology classiﬁcation. Similarly, a peptide peak is assigned
the RT and m/z features at the ﬁrst data generation step, the num-
ber of matched amino acids at the identiﬁcation step, the type of
Table 1
Proteomic objects and associated features.
Proteomic
objects
Spot (protein) or Peak (peptide)
Workﬂow
steps
Data generation (2-DE or LC–MS) Differential analysis Identiﬁcation (MS–MS/MS) Metadata analysis (KEGG,
GO)
Features MW, pI, volume. . . or RT, intensity,
m/z, . . .
Fold factor, p-value, cluster ID, PCA
loading, . . .
Conﬁdence, score, coverage, number of matched
peptides, . . .
Pathway, biol.process, . . .
Possible features that may get associated with a proteomic object (protein spot or LC–MS peak) at different steps of a typical proteomics analysis workﬂow.
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biological process and pathway name at a metadata analysis step,
and so on. We should mention here that features from the metada-
ta analysis step (e.g., gene ontology terms, pathway information)
could emerge from different sources (e.g., databases, tools), and
in the case of being categorical labels, they should be ﬁrst mapped
to numerical values. Table 1 lists examples of features that may
emanate at different steps of the proteomics analysis workﬂow
and are all associated with the same proteomic object.
In general, if a proteomics analysis workﬂow consists of M
steps, we model a proteomic object(x,y), situated at position
(x,y) of the map, as an ordered set of features F(x,y) = fij,
i = 1,2,. . .,M, j = 1,2,. . .,Ni, where Ni is the number of new fea-
tures of object(x,y) added at workﬂow step i. A Proteomic Fea-
ture Map (PFM) is a synthetic map and a generalized notation
depicting for every object (x,y) a user-selected subset of features
from the set F(x,y), not all necessarily produced at the same
workﬂow step. The PFMs introduced here are similar to the ap-
proach presented by Dolan et al. [18], where chromosomes are rep-
resented as linear spatial objects and the genome sequence
features (e.g., gene structure, GO function) are encoded on the
chromosomes using graphic symbols (e.g., shape and color). Impor-
tantly, the proposed PFMs intend to provide an abstraction for pre-
senting and visualizing the distribution of proteomic object
features on a map in a uniﬁed manner for both 2-DE-MS and LC–
MS workﬂows. Therefore, our approach is independent of the phys-
ical mechanism which generated the proteomic objects, allowing
the possible comparison of PFMs even across different experimen-
tal methods (e.g., a user could compare a 2D gel map and a LC–MS
protein map, both being parts of the same biological study).
In this work, we also demonstrate how two-feature PFMs can be
visualized efﬁciently using spheres. Spherical glyphs can capture
better than circles the potential partial overlapping of objects
and through their size and color it is possible to encode and pres-
ent effectively at least two proteomic object features at a time. We
currently exploit only two main attributes of a sphere, speciﬁcally
its size and color, to help us encode and visualize jointly proteo-
mics feature pairs on the samemap. In principle, more sphere attri-
butes could be exploited (e.g., brightness, texture) to encode
additional features. However, the selection of the optimal numberTable 2
Proteomic Feature Maps and feature pairs visualized.
Scenario
2-DE MS 1 Gel map
2 Differential map
3 Identiﬁcation map
Combined map
LC–MS 4 Peptides map
5 Proteins map
The speciﬁc features associated with the spheres size and color attributes in the six diffof visualization attributes is not a trivial task due to the fact that a
useful information presentation method is not necessarily the one
that tries to combine as many features as possible, something that
may lead to data overload. We believe that the number of features
to visualize simultaneously on a sphere depends on the speciﬁc
context of the data analysis and will be subjected to further
research.
We have selected ﬁve indicative example cases (scenarios) to
demonstrate how the visualization of PFMs facilitates the interpre-
tation of the results obtained at different steps of either a 2-DE or a
bottom-up LC–MS based proteomics data analysis (Fig. 1). In each
scenario, we utilize the size and color of the spheres to encode and
visualize a different pair of proteomic object features. Table 2 sum-
marizes the ﬁve scenarios along with the corresponding PFM visu-
alizations to be presented and discussed. We should mention that
the scenarios we chose to present are only indicative examples of
what we consider as to be interesting pairs of features for visuali-
zation at each step of the analysis. Therefore, they are only used as
a proof of concept and do not explore extensively all possible fea-
tures combinations. One of the key aspects of the proposed meth-
odology is ﬂexibility, so that it can work with any combination of
features that the user may select to explore visually. New PFMs
visualizations can be generated easily using any conventional
workstation and the OpenDX, a visualization software that has
been extensively used in several scientiﬁc domains and is freely
available in the public domain (see Supplementary material). In
addition, they can be moved, rotated, zoomed and reveal the size
and color values of an object by clicking on the corresponding
sphere (the interactive OpenDX features are not presented in the
paper). The code we have used to create the PFMs discussed in this
paper is included in the Supplementary material.
2.1. The Gel map: Scenario 1
For a typical 2-DE gel image, as the one shown in Fig. 3, panel A,
the PFM representation (gel map) is provided in Fig. 3, panel B. The
gel map is constructed after applying image analysis on the 2D gel,
in our case using the PDQuest image analysis tool [19]. In the gel
map, the center of a sphere is placed at the pixel of maximum
intensity of the modeled spot (i.e., the (x, y) position of the spotSphere’s attribute
Size Color
Spot volume Spot intensity
At least one Statistical test passed log2(fold factor)
Number of matched peptides Identiﬁcation Score
Number of matched peptides log2(fold factor)
Number of matched amino acids log2(115/116 ratio)
Coverage log2(115/116 ratio)
erent PFM visualizations (four 2-DE MS, two LC–MS) discussed in the paper.
Fig. 3. Original 2-DE gel image and Gel map. (A) A typical 2-D gel image from the bladder cancer dataset and zoomed areas showing: (A1) a complex region of severely
overlapping spots, (A2) a spots streak and (A3) faint spots. (B) The corresponding gel map visualization: PFM=[volume, intensity] and zoomed areas showing how spheres:
(B1) make spot boundaries obvious so that the individual spots detected in the complex region can be discerned, (B2) help visualizing formed streaks and, (B3) make it visible
which faint spots have been detected by the image analysis software. In the size bar the values are in OD*IU2 units; in the color bar the values are in OD units (where OD is the
optical density and IU the image units as described in [19]).
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corresponding proteins MW and pI. With the sphere size we chose
to represent the spot volume (i.e., the ‘‘spot quantity” extracted by
PDQuest) and with color the spot intensity value (i.e., the ‘‘peak
value” in PDQuest). This aims in creating a representation that
although looks very similar to the real gel image, it focuses on
two interesting spot features while abstracting away other gel de-
tails. By comparing the two panels of Fig. 3, we observe that the gel
map provides a faithful, pseudo-3D representation of the gel image
that effectively captures the essential information, as extracted by
the speciﬁc image analysis software used.
Three regions of the gel image (see red boxes) have been iso-
lated, magniﬁed and compared side-by-side to the corresponding
regions in the PFM. Spheres that appear to be missing from the
gel map correspond to faint spots that have not been detected by
the image analysis software, although they may be visible in the
gel image. Thus, the gel map offers a summary of all detected spots,
along with their abundance information, and allows noticing easily
non-detected faint spots (i.e., potential false negatives) when used
in conjunction with the original gel image. Since all spots are mod-eled using the same visualization glyph (i.e., sphere), it becomes
easier to perceive relative differences in spot volume. More impor-
tantly, the use of a greater range of colors, which replaces gray-
scale, certainly helps us comprehend better the intensity
distribution of the spots on the gel.
Since the proposed PFM visualization takes place after image
analysis, the gel map offers a way to summarize visually important
decisions that the available image analysis software has made, cor-
rectly or incorrectly, in dealing with three well known challenges
in 2-DE image analysis [20]: partitioning gel regions with overlap-
ping spots, removing streaks, and detecting faint spots. For exam-
ple, by comparing panels A1 and B1 of Fig. 3 we can easily
distinguish and even count the number of spots that the image
analysis software has extracted in a complex region of severely
overlapping spots, see their location and assess their relative abun-
dance. No matter how the image analysis software partitions a
complex spot region of the gel image into individual spots (i.e.,
with or without operator assistance), the ﬁnal result will be a set
of partially overlapping spot regions which will all be visible on
the gel map as partially overlapping spheres (see Fig. 3, panel
648 E.G. Giannopoulou et al. / Journal of Biomedical Informatics 42 (2009) 644–653B1). The degree of the spheres overlapping can be easily controlled,
by adjusting two parameters (i.e., scale and ratio values in the
‘‘AutoGlyph” module of OpenDX [21]) which determine the
spheres size. Moreover, in the gel map (Fig. 3, panel B2) we can
identify a vertical streak of spots which is not clearly visible in
the gel image (Fig. 3, panel A2). Finally, detected faint spots that
are not clearly separated from the image background in the image
(Fig. 3, panel A3) are unambiguously visible on the map (Fig. 3, pa-
nel B3).
It is important to note that by no means does the proposed visu-
alization intend to replace the real 2D gel image in the proteomics
workﬂow. The gel map serves as a more abstract and generalized
visualization approach that:
 draws attention to important user-selected spot features (e.g.,
spot volume, intensity),
 provides a mechanism for quick inspection of all detected spots
and their main characteristics,
 assists in disambiguating complex regions with overlapping
spots, vertical streaks, as well as detected faint spots,
 aids in locating faint spots that have not been detected by the
image analysis software and may deserve user attention.
2.2. The Differential expression map: Scenario 2
The objective of the differential expression data analysis step
(Fig. 1, panel 1) is to identify spots with expression levels whichFig. 4. Two maps for the same objects (spots) generated at two different steps of the 2-
steps. (A) Visualization of a differential expression map: PFM=[at least one statistic
spots that have passed at least one of the two statistical tests applied. (B) Visualization
score]. By inspecting jointly the twomaps we observe: in region 1 (red box), several up r
that have been identiﬁed with high conﬁdence and in region 2, two spots, an up and a d
PFM=[number of matched peptides, volume log2 fold factor]. One feature com
advantages of this map are comparable to those coming from the joint comparison of thdiffer considerably in different biological states (e.g., disease vs.
non disease). Typically, in order to locate the differentially ex-
pressed spots in the original gel, the user has to go back and forth
between the master gel image, which is annotated with spot num-
bers, and lists or tables holding the results of a statistical or quan-
titative expression analysis for the spots in the matched set. The
motivation for creating a differential expression map (such as the
one of Fig. 4A) is to summarize visually the performed differential
expression analysis and assist the user to ﬁnd the spots which mer-
it undergoing MS-based identiﬁcation.
In the bladder cancer experiment, a spot was considered differ-
entially expressed if it either passed at least one of two different
statistical tests or exhibited a volume fold factor exceeding a spe-
ciﬁc threshold (see Section 4, Methods). In order to integrate this
information that was distributed in different tables and not di-
rectly linked to the gel image, for the differential expression map
of Fig. 4A we have used the binary feature ‘‘at least one statistical
test passed” (with possible values True = 1, False = 0) for the size
and the logarithm (base 2) of the volume fold factor for the color of
the spheres. Therefore, in our implementation, large-size green/red
spheres model protein spots that were found to be signiﬁcantly up/
down regulated respectively (i.e., having log fold factor value lar-
ger/smaller or equal to 1/1), whereas spots that passed at least
one statistical test but exhibit log fold factor in the range [1,
1] are depicted as large blue spheres. Finally, spots that did not
meet any of the above two criteria (i.e., exhibited volume fold fac-
tor in the range of [1, 1] and did not pass any statistical test)
have been included in the map, but shown as minuscule blueDE analysis workﬂow and one map combining features from two different analysis
al test passed, volume log2 fold factor]. Large spheres correspond to protein
of an identiﬁcation map: PFM=[number of matched peptides, identification
egulated differentially expressed spots (shown as green and large spheres in Fig. 4A)
own regulated that have not been identiﬁed. (C) Visualization of a combined map:
es from the Differential analysis step and one from the Identiﬁcation step. The
e two previous maps.
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map and facilitate possible comparisons between the maps.
The proposed PFM visualization provides an effective visual
summary of the differential expression results. By using the differ-
ential expression map the user can easily:
 reveal possible regulation patterns and trends, or their absence,
in the proteomics data,
 make interesting observations regarding the methods or the
data set used for the differential expression analysis.
Speciﬁcally, in the PFM of Fig. 4A, we observe that:
 among the differentially expressed spots (large spheres) there is
almost the same percentage of up (green) and down (red) regu-
lated proteins, a remark that could be indicative of the regula-
tion trend in a speciﬁc biological state,
 there exist several large size blue spheres, indicating that there
are spots that have passed at least one statistical test but did not
meet the 2-fold criterion. This observation points out the impor-
tance of using complementary more than one criteria for the dif-
ferential expression analysis.
2.3. The Identiﬁcation map: Scenario 3
An identiﬁcation map is a PFM that may be produced at the end
of a MS-based protein identiﬁcation step, so as to help the user re-
view easily the results of the identiﬁcation process, instead of hav-
ing to inspect a large table summarizing the identiﬁcation output.
In the scenario presented here, we use spheres to visualize the out-
put of a typical peptide mass ﬁngerprinting experiment. More spe-
ciﬁcally, the size of the sphere encodes the number of matched
peptides and the color of the sphere encodes the score (produced
by the Mascot [22] search engine) of the modeled protein spot.
These two features, when combined, not only summarize the re-
sults of the MS-based identiﬁcation procedure, but also provide
an estimate of its reliability.
In the speciﬁc example of the bladder cancer dataset (see Sec-
tion 4, Methods), all differentially expressed protein spots (see
Fig. 4A) were further processed for identiﬁcation through trypsin
digestion and peptide mass ﬁngerprinting. The resulting identiﬁca-
tion map is shown in Fig. 4B. A high score and a large number of
matched peptides (i.e., yellow-green and large size spheres) sug-
gest increased conﬁdence on the identiﬁcation result. Proteins that
remained unidentiﬁed after the database search appear as red
spheres. Spots not picked for MS analysis are again shown as
minuscule blue spheres to maintain visual reference to the corre-
sponding differential expression and gel maps.
In summary, by inspecting the identiﬁcation map, the user can:
 discover effortlessly, due to their assigned color, the unidentiﬁed
spots that might need further analysis,
 make rapid observations that can either strengthen or disprove
the identiﬁcation results.
Speciﬁcally, in the PFM of Fig. 4B we can notice that:
 seven (7) spots, out of the total of 32 (22%), that can be easily
located on the map, were not identiﬁed by the database search
(red spheres) and could possibly require additional
investigation,
 the size of the spheres gets smaller as we move towards the bot-
tom part of the map. This is an expected observation that veriﬁes
the positive correlation of MW to the number of matched
peptides.Additionally, a joint examination of the differential expression
and the identiﬁcation maps (Fig. 4A and B) can reveal spots of great
interest to the user that merit further analysis. This could occur
either because these spots are both differentially expressed and
identiﬁed with high conﬁdence, indicating that they may have a
particular signiﬁcance to the performed study, or because although
they were found to be up- or down-regulated, they were not iden-
tiﬁed at all. In particular, it would be difﬁcult to extract the follow-
ing interesting information, if it had not been for the proposed
integrative visualization:
 there are many large size spheres with yellow or green color in
Fig. 4B, meaning that most differentially expressed spots of
Fig. 4A have been also identiﬁed with high conﬁdence,
 there are up-regulated spots that have passed at least one statis-
tical test (e.g., see the large green spheres inside the box of
region 1 in Fig. 4A) and have also been identiﬁed with high con-
ﬁdence (large yellow-green spheres in region 1 of Fig. 4B). This
visualization assists the user to select proteins that deserve fur-
ther experimental investigation through immunoassays and
other approaches.
 there exist some up- or down-regulated spots (spheres inside
region 2 of Fig. 4A) that could not be identiﬁed by the peptide
mass ﬁngerprinting MS analysis (small red spheres in region 2
of Fig. 4B) and might possibly need further investigation. Actu-
ally, subsequent analysis of these spots by alternative strategies
revealed that these proteins were highly modiﬁed (Vlahou, A.,
unpublished observation).
More importantly, we can easily create a PFM that integrates
visually features from different analysis stages, as it is shown in
Fig. 4C. In this combined map, the color of the spheres represents
the fold factor and the size the number of matched peptides, fea-
tures coming from the differential analysis and identiﬁcation
workﬂow steps, respectively. The beneﬁts of the combined map
are similar to those coming from the joint comparison of the two
previous maps (i.e., differential expression and identiﬁcation). For
example:
 we can now easily locate the up regulated and identiﬁed with
high conﬁdence proteins (upper right part of the map),
 we observe that the majority of the differentially expressed
spots (red and green spheres) were identiﬁed by more than 20
matched peptides (shown by the size of their spheres), which
indicates the increased reliability of the identiﬁcation result.2.4. The Peptides map: Scenario 4
A bottom-up LC–MS experiment provides information about
the identity, and when combined with stable isotope labeling tech-
niques, about the relative expression levels of thousands of pep-
tides. Similarly to a protein spot, a peptide peak can also be
considered as a proteomic object placed at coordinates
(x,y)=(m/z, RT) on a map. The power of this simplistic, yet po-
tent, argument leads to the uniﬁed usage of spheres to visualize
interesting peptide features by exploiting the sphere size and color
attributes.
In the LC–MS experiment (see Section 4, Methods) we have
used the ProteinPilot software package by Applied Biosystems
[23] to perform protein identiﬁcation and quantiﬁcation. Among
the several peptide related features that it generates, we have
chosen to associate the number of matched amino acids (AA)
with the sphere size, in order to provide a measure on the pep-
tides identiﬁcation conﬁdence. We have deﬁned the following
three classes:
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expression ratio]. (A1) Zoomed area of the peptides
conﬁdence. (B) Proteins map visualization: PFM=[cover
conﬁdence in the MW < 100 kDa region. A small percentaSmall size sphere
C2: 8 AA 6matched sequence length 6 2 AA Medium size sphere
C3: matched sequence length >12 AA Large size sphereWe tend not to trust the identiﬁcation of peptides that fall in
class C1, but our conﬁdence is raised considerably for peptides in
C2 and C3. This classiﬁcation scheme takes into account that the
LC–MS experiments generate MS spectra having a mass accuracy
of 6 10 ppm (see Section 4, Methods) for both precursor and prod-
uct ions [24].
Additionally, we want to gain an indication of the regulation
trend of our sample and be able to distinguish easily the up- and
down-regulated peptides from those exhibiting no signiﬁcant
expression change in two biological conditions, based on the 115116
quantiﬁcation ratio (see Section 4, Methods). In order to get a sym-
metric range, we have used the logarithm (base 2) of the up/down
expression ratio log2(115116). As in scenario 2, green/red spheres marked zoomed areas. (A) Peptides
map, showing the existence o
age, proteins log2(
115
116) exp
ge of them has been differentipeptides that exhibit log fold factor values larger/smaller or equal
to 1/1, respectively. All other, non-differentially expressed, pep-
tides are depicted as blue spheres in order to preserve an overall
inspection of the LC–MS data. The map includes only the peptides
which are contributing to the calculation of the iTRAQ ratio of the
identiﬁed proteins (relative quantiﬁcation), so as to achieve consis-
tency between the LC–MS peptides map (Fig. 5A) and the proteins
map (Fig. 5B) that will be discussed later in Scenario 5.
The peptides map of Fig. 5A summarizes visually the whole LC–
MS experiment. Due to the high density of the map it may seem
difﬁcult in the beginning to discern sphere size differences; how-
ever, this becomes an easier task when we zoom to speciﬁc areas
of the map (see Fig. 5A1). Importantly, the color attribute helps
us spot the differentially expressed peptides more easily on the
map than in vast tables and lists. Using OpenDX, we can zoom in
any region of the map and construct visually an estimate for the
peptide identiﬁcation conﬁdence and the ratio of expression levels
in the two biological states of interest. The larger the spheres size,map visualization PFM=[number of matched amino acids, peptides log2(115116)
f vertical streaks and peptides with different expression levels and identiﬁcation
ression ratio]. There exist several proteins that have been identiﬁed with high
ally expressed.
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entially expressed peptides that they represent.
The peptides map proves to be very useful in many different
ways. First, by using a peptides map that summarizes our LC–MS
experiment, we can rapidly detect patterns that provide explana-
tion and veriﬁcation of our ﬁndings. Most importantly, the exami-
nation of a peptides map can reveal details of the experimental
conditions or of the methodological part of the experiment. Last
but not least, the inspection of the peptides map can assist an ana-
lytical chemist to adjust the experimental parameters and reﬁne
the experiment, in order to obtain results that are more accurate
and of higher quality.
More speciﬁcally, in the peptides map of Fig. 5A we observe that
the majority of the spheres is blue, meaning that only a small frac-
tion of the peptides was found to be differentially expressed. This
observation is in agreement to other protein expression studies
conducted on prostate tissue [25–27]. Moreover, in the zoomed
area of Fig. 5A1 we notice that some spheres form vertical streaks,
indicating the ‘‘carryover” effect [28]. If such a pattern is observed,
the user can adjust the experimental parameters (e.g., MS/MS
acquisition time limit) in order to permit the acquisition of lesser
abundant peptides that tend to partially co-elute with the higher
abundant peptides generating the observed streaks.
Inspection of Fig. 5A also reveals that in this experiment there
are more hydrophobic (RT between 95 and 155 min) than hydro-
philic peptides (RT between 35 and 95 min), a ﬁnding that is in
accordance to the experimental conditions used during the protein
extraction process. Furthermore, an increased density of peptides
is observed in the mid-point of the map. This is explained by the
50% aqueous and 50% organic mobile phase composition, in which
a large number of peptides tend to elute due to their increased sol-
ubility property. When observing this type of pattern, the analyst
may choose to reﬁne the LC–MS experiment, so as to extend the
gradient chromatographic conditions and thereby improve the
quality of the tandem mass spectra.
2.5. The Proteins map: Scenario 5
The motivation for the creation of a proteins map is the fact that
it allows us to view protein features originating from a LC–MS
based bottom-up proteomic analysis in a manner that resembles
a 2D gel map. We beneﬁt from the capability of the ProteinPilot
software package to export a protein-based summary of the LC–
MS analysis results, in order to create a list of the identiﬁed pro-
teins, and then we use their theoretical MW and pI (see Section
4, Methods) as coordinates for the protein objects representing
them as spheres on the map. It should be noted here, that the pI
of an identiﬁed protein may differ from its theoretical pI due to
PTMs or modiﬁcations attributed to the experiment (e.g., pharma-
ceutical drugs, toxicants and so on). In the proteins map of Fig. 5B,
we have chosen to represent the coverage of identiﬁed proteins
with sphere size, since it provides a measure of conﬁdence on
the identiﬁcation, and the log2(115116) expression ratio, at the protein
level, with color. By combining these two features, the user can
have at once a general estimation of the protein identiﬁcation
and quantiﬁcation. ProteinPilot estimates the 115116 ratio as a
weighted average of the corresponding ratios of the identiﬁed pep-
tides that have been matched to a certain protein [29] (shown in
the peptide map of Fig. 5A). Therefore, in the proteins map the dif-
ferential expression is visualized at the proteins level, while in the
peptides map it is visualized at the corresponding peptides level.
The proteins map allows us to acquire an estimate of the pro-
teins nature in terms of their RT and MW distribution. Moreover,
similarly to the peptides map, the inspection of a proteins map
can help in detecting patterns, which verify our ﬁndings, or in
revealing regulation trends in a speciﬁc biological state. Finally,the proteins map visualization can assist in the reﬁnement of the
LC–MS method or in the design of more targeted LC–MS based
approaches.
More speciﬁcally, the quantitative distribution of the proteins
found with the LC–MS based proteomics approach is depicted
in Fig. 5B (in accordance to their theoretical MW and pI values).
In this ﬁgure there are 454 spheres corresponding to an equal
number of identiﬁed proteins (only four identiﬁed proteins with
MW P400 kDa are not shown so as not to suppress the ﬁgure).
The proteins map makes apparent that a signiﬁcant number of
proteins having a theoretical MW <15 kDa and >200 kDa along
with proteins having very acidic (pI < 4) and very basic character
(pI > 10) were found by this approach. These characteristics dem-
onstrate the ability of the LC–MS based proteomic method, as
used in scenario 5, in analyzing such categories of proteins.
Additionally, in the proteins map we can observe that the
majority of the spheres are blue, indicating that only a small num-
ber of proteins were found to be differentially expressed [25–27],
as expected since most peptides are also blue in Fig. 5A. Using
OpenDX we can also zoom in any desired region and obtain a quick
visual impression on the identiﬁcation conﬁdence for the differen-
tially expressed proteins.
The proteins map output can also guide us in the reﬁnement of
the LC–MSmethod in a variety of ways. For example, it allows us to
locate highly abundant proteins (e.g., myosin, actin, keratin),
which, not always but often, have a high tryptic peptide coverage
(large spheres). These peptides could then be subjected to more
effective chromatographic separation or may be candidates for
the construction of exclusion lists to facilitate the detection of les-
ser abundant tryptic peptides, leading to the identiﬁcation of lesser
abundant proteins (i.e., proteins that participate in cell signaling
pathways, constitute components of cell membranes). The ability
to visualize proteins with high peptide coverage imparts a greater
possibility in discriminating important protein isoforms (varying
by a few peptides or amino acid residues) or in the identiﬁcation
of peptides exhibiting PTM features (e.g., phosphorylation of a ser-
ine or threonine). Importantly, the PFMs permit the investigator to
design more targeted LC–MS based proteomic approaches for the
analysis of a subset or even distinct proteins of interest, based on
the use of more selective chromatographic chemistries (i.e., anti-
body or chemical afﬁnity chromatography).
3. Conclusions
We have introduced Proteomic Feature Maps, a concept that
allows us to integrate visually features of proteomic objects
(i.e., 2-DE protein spots or LC–MS peptide peaks), possibly pro-
duced at different steps of a proteomics analysis workﬂow, in a
uniﬁed manner. The innovative aspect of this work is that more
than one features of each proteomic object can be visualized
simultaneously by utilizing the size and color attributes of a
sphere. To the best of our knowledge this simple, yet elegant, idea
has not been used before in proteomics data visualization. We
have demonstrated that the proposed visualization approach is
applicable in a uniﬁed manner to both 2-DE and LC–MS differen-
tial proteomics analysis. By using ﬁve representative example
cases we have shown that the visual inspection of PFMs reveals
useful information for the experiment at different steps of the
analysis. In particular, the PFMs visualization allows a better
understanding of the whole dataset, facilitates the detection of
patterns and differential expression trends and assists in the
reﬁnement of a proteomics experiment. It is important to empha-
size that the feature pairs selected for presentation here are just
indicative examples of what is possible to visualize with PFMs.
In principle, any pair of features (numerical or categorical) of
interest to the user could be used.
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realize the PFMs visualizations, we used OpenDX, a public domain
software tool, which can be effortlessly installed and is easy to use.
OpenDX is ﬂexible, interactive and can directly manipulate images
(e.g., rotate, zoom). Additionally, our prototype implementation
provides a control panel, where one can change the color map of
a PFM very easily in order to adapt it to his/her needs (see Supple-
mentary material). However, there are certain limitations associ-
ated with using OpenDX; for example, the simultaneous
visualization of a third proteomic feature on spheres, by exploiting
their lighting or transparency properties, was not an achievable
task.
Currently, we are working on the development of a Java-based
interactive tool for proteomics visualization that integrates the
PFMs concept and the use of spheres into an interactive user-
friendly software package. Since this tool will be speciﬁc to proteo-
mics data, we intend to allow importing sets of features from sev-
eral formats that start to play a signiﬁcant role in computational
proteomics (e.g., mzXML [30], AGML [31]) by incorporating data
ﬁle converters. Additionally, we plan to explore and possibly ex-
tend the application of PFMs in other prevalent proteomic methods
such as protein arrays. Last but not least, we are investigating the
optimal number of features that could be effectively visualized
jointly on a sphere depending on the context of the proteomics
data analysis. Our ultimate objective is to be able to support the
integrative visualization of at least triplets of user-deﬁned proteo-
mic object features, through an easy-to-use interface in an interac-
tive software environment. Therefore, we expect to tackle the
challenge of multidimensional proteomics data visualization in
even more effective ways.
4. Methods
4.1. Datasets
The ﬁrst dataset used in this paper (Scenarios 1, 2 and 3), re-
sulted from a bladder cancer study [32] aimed at understanding
the molecular mechanisms of cancer aggressiveness and the
development of novel biomarkers for its oncological management.
More speciﬁcally, the study involved the 2-DE based proteomics
analysis of two lineage related bladder cancer cell lines, which
differ in their metastatic potential. Five 2-DE gels per cell line
(i.e., two matched sets of ﬁve gels each) were generated and com-
pared, representing the cancerous and its more aggressive state
respectively.
Panel 1 in Fig. 1 depicts the main steps of the data processing
workﬂow in the 2-DE bladder cancer experiment. In step 1, gel
images were analyzed using the PDQuest 7 software package (Bio-
Rad) [19]. In step 2, differentially expressed protein spots were ex-
cised manually, or automatically, using the ProteineerSp Protein
picker (Bruker Daltonics) [33] and subsequently were digested
using trypsin. A spot was considered as differentially expressed if
it passed at least one of the two statistical tests (Students t-test,
Mann–Whitney test (p <0.05, a = 0.95) [34]) or satisﬁed the 2-fold
quantitative criterion (i.e., the ratio of mean spot volumes in the
two biological states under consideration to be larger than 2). In
step 3, differentially expressed spots were identiﬁed using peptide
mass ﬁngerprinting. In brief, the peptide masses were determined
by MALDI-TOF-TOF MS (Ultraﬂex TOF/TOF, Bruker Daltonics, Bre-
men, Germany) [14]. Peptide matching and protein searches were
performed automatically with the Mascot Server 2 [22,35]. During
this search the peptide masses were compared with the theoretical
peptide masses of all available proteins from Homo sapiens in the
Swiss-Prot [36] database.
The second dataset used in this paper (Scenarios 4 and 5) was
generated in the context of a LC–MS study [37] based on quantita-tive proteomic methodologies using iTRAQ reagents, and aimed at
identifying new biomarkers for prostate cancer. The dataset was
created by analyzing six prostate tissue specimens used to isolate
proteins originating from the following two biological states: be-
nign prostate hyperplasia (BPH) (n = 3) and prostate cancer (PCA)
(n = 3). These specimens were extracted for their protein content
and then subjected to tryptic digestion. The label designation 116
corresponds to the protein digest originating from the BPH speci-
mens and labeled with the iTRAQ reagent which produces the
116 reporter ion during peptide fragmentation. Similarly, the label
designation 115 corresponds to the protein digest originating from
the PCA specimens and labeled with the iTRAQ reagent which pro-
duces the 115 reporter ion during peptide fragmentation. There-
fore, the 115116 ratio is indicative of the differential expression
between the two biological states of interest.
Panel 2 in Fig. 1 summarizes the steps of the prostate cancer LC–
MS experiment workﬂow. In step 1, the protein extracts were tryp-
tic digested and the resulting peptides were labeled with iTRAQ
isobaric tagging reagents followed by fractionation using strong
cation exchange-hydrophilic interaction chromatography. Prior to
sample analyses and up to a time duration of 12 h, the TOF MS
instrument was externally calibrated. The individual fractions gen-
erated were online LC–MS analyzed with reverse phase capillary LC
hyphenated with a nano-ESI source retroﬁtted to a hybrid quadru-
pole time-of-ﬂight MS/MS system. In step 2, all tryptic peptide MS/
MS spectra were subjected to an internal calibration process fol-
lowed by protein quantiﬁcation and identiﬁcation, using the Pro-
teinPilot 2.0 Software (Applied Biosystems, San Jose, CA, USA)
[23]. It is important to note that the combined use of the external
followed by internal calibration schemes resulted in a mass accu-
racy of 610 ppm for all peptide MS/MS spectra [37]. The database
searching was based on the Homo sapiens species against the NCBI
non-redundant (nr) protein database [38] and the detected protein
threshold (i.e., the minimum protein conﬁdence) [29] was set to
90%.
4.2. Software
The software package OpenDX [39,40] was used to visualize all
the PFMs presented in this paper. OpenDX is a modular visualiza-
tion environment, which allows building complex graphical sys-
tems from simple elementary tasks. Originally, it was developed
by IBM as a Visualization Data Explorer, but it is now available
as open source software package. More speciﬁcally, it is a cross-
platform tool that consists of a graphical user interface (GUI), an
execution environment and a data model used to build a well-de-
ﬁned representation of data. OpenDX supports a visual data-ﬂow
programming model: the data provided to OpenDX ﬂow through
a network of modules, get processed and generate an image.
Numerous modules are available for importing data, creating
glyphs, shapes and isosurfaces, assigning color to data, adding text
and so on. Furthermore, OpenDX adopts an open architecture in
which user-deﬁned modules can be added. Thus, using OpenDX
modules, the basic components of the data-ﬂow programming
model, we generated the code for producing the PFM visualizations
described in this paper (code is available in Supplementary
material).
To create the presented PFMs, we export the features of interest
in a text-based column representation compatible with Microsoft
Ofﬁce Excel, either from the PDQuest Image Analysis software (in
the case of 2D gel images) or from ProteinPilot software (in the
case of a LC–MS experiment). We transform the exported data into
a tab delimited text ﬁle, using a’.data’ extension which is one of the
input formats accepted by OpenDX. It should be noted that data
originating from any proteomics analysis software package avail-
able in a laboratory can be easily imported into OpenDX, as long
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used for a PFM visualization consists of four columns: the ﬁrst
two are the Cartesian (x,y) coordinates for the proteomic objects
in the map, and the last two are the values of the selected feature1
and feature2, to be visualized by using the spheres size and color
attribute respectively. For brevity, such a PFM visualization is de-
noted in the paper as PFM=[feature1, feature2].
Finally, we have used two functions (isoelectric() and mol-
weight()) of the MATLAB Bioinformatics Toolbox [41] to compute
the theoretical pI and MW for the proteins coming from the LC–
MS analysis, which are the sphere coordinates for the map of Sce-
nario 5.
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